Accessibility settings

This paper is in the following e-collection/theme issue:

Reviews in AI (188) Natural Language Processing (1304) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (274) Artificial Intelligence (4850)

Published on in Vol 5 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/77732, first published .
Gloved hands pouring blue and white capsules from a white bottle into an open palm.

Application of Language Models for the Analysis of Adverse Drug Events in Pharmaceutical Research and Development: Scoping Review

Application of Language Models for the Analysis of Adverse Drug Events in Pharmaceutical Research and Development: Scoping Review

Authors of this article:

Oren Schreier1 Author Orcid Image ;   Anthony Yazdani1 Author Orcid Image ;   Ioannis Galdadas2, 3, 4 Author Orcid Image ;   Ryme Kabak5 Author Orcid Image ;   Francesco Luigi Gervasio2, 3, 4, 6 Author Orcid Image ;   Gang Mu7 Author Orcid Image ;   Douglas Teodoro1 Author Orcid Image
Article Authors Cited by (2) Tweetations Metrics

Journals

  1. Wójcik S, Rulkiewicz A, Domienik-Karłowicz J. Artificial Intelligence Readiness in Clinical Trial Operations: A Narrative Review and Site-Level Governance Framework. Healthcare 2026;14(16):2519 View
  2. Thompson D, Mitchell S, Adams R, Brown J, Lee M. What Happens to the Safety Case When Artificial Intelligence Enters Pharmacovigilance? An Umbrella Review from Intake to Signal Action. Archives of Pharmacy Practice 2026;17(3):46 View